The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: results from the PIOfix study.

@article{Schndorf2011TheFC,
  title={The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: results from the PIOfix study.},
  author={Thomas Sch{\"o}ndorf and Petra B. Musholt and Cloth Hohberg and Thomas Forst and Ute Lehmann and Winfried Fuchs and Mirjam L{\"o}big and Juergen Mueller and A Pf{\"u}tzner},
  journal={Journal of diabetes science and technology},
  year={2011},
  volume={5 2},
  pages={426-32}
}
BACKGROUND Type 2 diabetes mellitus (T2DM) is characterized by a proinflammatory and procoagulant condition. This study investigates the impact of a pioglitazone plus metformin therapy on biomarkers of inflammation and platelet activation in comparison to a treatment with glimepiride plus metformin. METHODS The study was designed as a multicenter, randomized, double-blinded two-arm trial. Patients with T2DM and dyslipidemia under metformin monotherapy with hemoglobin A1c value between 6.5… CONTINUE READING
9 Citations
36 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 36 references

PIOace-Study: pioglitazone, but not ramipril improves thrombocyte function and reduces low grade inflammation in non-diabetic patients with increased cardiovascular risk. Diabetologia

  • A Pfützner, M Hanefeld, +4 authors T. Forst
  • 2009

Similar Papers

Loading similar papers…